The receptor for advanced glycation end-products enhances lung epithelial wound repair: An in vitro study.


Journal

Experimental cell research
ISSN: 1090-2422
Titre abrégé: Exp Cell Res
Pays: United States
ID NLM: 0373226

Informations de publication

Date de publication:
15 06 2020
Historique:
received: 30 03 2020
revised: 17 04 2020
accepted: 19 04 2020
pubmed: 25 4 2020
medline: 1 1 2021
entrez: 25 4 2020
Statut: ppublish

Résumé

Re-epithelialization of the alveolar surface is a key process of lung alveolar epithelial barrier repair after acute lung injury. The receptor for advanced glycation end-products (RAGE) pathway plays key roles in lung homeostasis, and its involvement in wound repair has been already reported in human bronchial epithelial cells. However, its effects on lung alveolar epithelial repair after injury remain unknown. We investigated whether RAGE stimulation with its ligands high-mobility group box 1 protein (HMGB1) or advanced glycation end-products (AGEs), alone or associated with RAGE inhibition using RAGE antagonist peptide, affects in vitro wound healing in human alveolar epithelial A549 cells. We further asked whether these effects could be associated with changes in cell proliferation and migration. We found that treatment of A549 cells with HMGB1 or AGEs promotes RAGE-dependent wound healing after a scratch assay. In addition, both RAGE ligands increased cell proliferation in a RAGE-dependent manner. Treatment with HMGB1 increased migration of alveolar epithelial cells at 12 h, independently of RAGE, whereas AGEs stimulated migration as measured 48 h after injury in a RAGE-dependent manner. Taken together, these results suggest that RAGE pathway is involved in lung alveolar epithelial wound repair, possibly through enhanced cell migration and proliferation.

Identifiants

pubmed: 32330509
pii: S0014-4827(20)30257-3
doi: 10.1016/j.yexcr.2020.112030
pii:
doi:

Substances chimiques

Glycation End Products, Advanced 0
HMGB1 Protein 0
Receptor for Advanced Glycation End Products 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112030

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest This work was supported by grants from the Auvergne Regional Council and the French Agence Nationale de la Recherche and the Direction Générale de l’Offre de Soins. RZ was funded by a PhD grant from the Ecole Doctorale des Sciences de la Vie, Santé, Agronomie, Environnement (ED SVSAE, ED 65, Université Clermont Auvergne). The funders had no influence in the study design, conduct, and analysis or in the preparation of this article. The authors state that they have no conflict of interest to declare in relationship with this work.

Auteurs

Ruoyang Zhai (R)

Université Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, France.

Raiko Blondonnet (R)

Université Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, France; Department of Perioperative Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Ebrahim Ebrahimi (E)

Université Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, France; Department of Perioperative Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Corinne Belville (C)

Université Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, France.

Jules Audard (J)

Université Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, France; Department of Perioperative Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Christelle Gross (C)

Université Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, France.

Helena Choltus (H)

Université Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, France.

Fanny Henrioux (F)

Université Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, France.

Jean-Michel Constantin (JM)

Sorbonne University, GRC 29, AP-HP, DMU DREAM, Department of Anesthesiology and Critical Care, Pitié-Salpêtrière Hospital, Paris, France.

Bruno Pereira (B)

Biostatistics Unit, Department of Clinical Research and Innovation (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France.

Loic Blanchon (L)

Université Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, France.

Vincent Sapin (V)

Université Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, France; Department of Medical Biochemistry and Molecular Genetics, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Matthieu Jabaudon (M)

Université Clermont Auvergne, CNRS, INSERM, GReD, Clermont-Ferrand, France; Department of Perioperative Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: mjabaudon@chu-clermontferrand.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH